UPDATED May 18, 2024
Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
1086 | HK$0.63 | -6.0% | 3.3% | HK$1.1b | n/a | PE5.2x | E21.8% | 0% | Consumer Durables | ||
1373 | HK$1.32 | 0% | -54.5% | HK$950.3m | n/a | PE7.8x | n/a | 8.5% | Retail | ||
35 | HK$1.21 | 7.1% | -38.6% | HK$3.4b | HK$2.00 | PB0.2x | E137.4% | 11.6% | Real Estate Management and Development | ||
842 | HK$1.48 | 0% | 24.4% | HK$2.0b | n/a | PE3.5x | n/a | 9.4% | Capital Goods | ||
302 | HK$1.31 | -3.0% | -39.4% | HK$3.6b | HK$2.53 | PS1.3x | E17.8% | n/a | Media | ||
2120 | HK$11.98 | 5.8% | n/a | HK$881.2m | n/a | PE9.5x | n/a | 3.6% | Healthcare | ||
1765 | HK$0.28 | 15.9% | -50.9% | HK$2.3b | n/a | PE390.5x | E53.9% | n/a | Consumer Services | ||
2256 | HK$3.74 | 8.4% | 38.0% | HK$2.4b | HK$8.20 | PS117.7x | E-2.3% | n/a | Pharmaceuticals & Biotech | ||
1600 | HK$4.59 | -1.3% | -22.1% | HK$4.4b | HK$5.16 | PE8.6x | E13.1% | 4.2% | Utilities | ||
520 | HK$2.18 | 0.9% | -55.4% | HK$2.4b | HK$2.17 | PB1.8x | E55.3% | 2.8% | Consumer Services | ||
9919 | HK$1.30 | 0.8% | -0.8% | HK$968.2m | HK$2.29 | PE8.3x | S14.1% | 12.8% | Media | ||
1426 | HK$2.10 | 6.1% | -12.1% | HK$3.0b | n/a | PB0.5x | n/a | 8.5% | Real Estate | ||
2342 | HK$0.74 | 8.8% | -49.0% | HK$2.0b | n/a | PE303.6x | n/a | 0% | Tech |